Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
about
Pharmacological management of dermatomyositis.Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer.Current perspective on rituximab in rheumatic diseases.Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer.
P2860
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Autoantibody levels in myositi ...... cell depletion with rituximab.
@en
Autoantibody levels in myositi ...... cell depletion with rituximab.
@nl
type
label
Autoantibody levels in myositi ...... cell depletion with rituximab.
@en
Autoantibody levels in myositi ...... cell depletion with rituximab.
@nl
prefLabel
Autoantibody levels in myositi ...... cell depletion with rituximab.
@en
Autoantibody levels in myositi ...... cell depletion with rituximab.
@nl
P2093
P2860
P356
P1433
P1476
Autoantibody levels in myositi ...... cell depletion with rituximab
@en
P2093
Ann M Reed
Chester V Oddis
Dana P Ascherman
Diane Koontz
Marc C Levesque
Rohit Aggarwal
Zengbiao Qi
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEV444
P577
2016-02-16T00:00:00Z